Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

NCT ID: NCT01221077

Last Updated: 2025-11-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 88 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-04-08
• Study Completion Date: 2014-09-01

Brief Summary

A multicenter, randomized, double-blind, placebo-controlled, phase 2 study of Erlotinib (Tarceva®) in combination with OSI-906 in Patients with Advanced non-small cell lung cancer (NSCLC) with Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene who are Chemonaive.

Detailed Description

Based on the recommendation of the Data Monitoring Committee, OSI-906 and matching placebo are no longer being administered as of 01 March 2013.

This is a multi-center, randomized (1:1), double-blind, placebo-controlled, phase 2 study. Patients will be stratified according to the following 2 parameters: (1) EGFR activating mutation type (exon 19 deletion versus exon 21 single point mutation); and (2) Eastern Cooperative Oncology Group (ECOG) performance status (0 vs. 1).

Conditions

NSCLC; Non Small Cell Lung Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Arm A: Erlotinib plus OSI-906

As of 01 March 2013, OSI-906 is no longer being administered

Group Type: EXPERIMENTAL

OSI-906

Intervention Type: DRUG

As of 01 March 2013, OSI-906 is no longer being administered

Erlotinib

Intervention Type: DRUG

Erlotinib administered orally

Arm B: Erlotinib plus Placebo

As of 01 March 2013, the matching placebo is no longer being administered

Group Type: PLACEBO_COMPARATOR

Erlotinib

Intervention Type: DRUG

Erlotinib administered orally

Placebo

Intervention Type: DRUG

As of 01 March 2013, the matching placebo is no longer being administered

Interventions

OSI-906

As of 01 March 2013, OSI-906 is no longer being administered

Intervention Type: DRUG

Erlotinib

Erlotinib administered orally

Intervention Type: DRUG

Placebo

As of 01 March 2013, the matching placebo is no longer being administered

Intervention Type: DRUG

Other Intervention Names

OSI-774; Tarceva

Eligibility Criteria

Inclusion Criteria

• Historically confirmed advanced NSCLC stages IIIB or IV
• Exon 19 deletion or exon 21 activating mutation in EGFR
• EGFR mutation status must be confirmed for participation in the study. EGFR can be performed either by central or local laboratory. If analysis is done locally, verifiable documentation confirming the EGFR mutation status must be submitted for review and approval by sponsor prior to randomization. If no local result is available, formalin-fixed, paraffin-embedded archival tissue representative of the tumor or, in the absence of archival tissue, a fresh tumor tissue sample of sufficient size to perform EGFR mutation analysis must be submitted centrally. Results of the central analysis must be available prior to randomization. Additionally, subjects should provide tissue blocks for biomarker central analysis whenever possible. Ideal tissue requirement: block with ≥5 mm2 tumor area sufficient to provide four 4-micron, and five 10-micron sections
• Measurable disease according to RECIST (version 1.1)
• ECOG performance status 0-1
• Must be able to take oral medication
• Fasting glucose <= 150 mg/dL (8.3 mmol/L). Concurrent use of non-insulinotropic anti hyperglycemic therapy is permitted if the dose has been stable for >= 4 weeks at the time of randomization
• Adequate hematopoietic, hepatic, and renal function as follows:

• Neutrophil count >= 1500/uL
• Platelet count >= 100,000/uL
• Serum creatinine <= 1.5 x Upper Limit of Normal (ULN)
• Potassium, magnesium, and calcium within normal limits (supplementation and re-testing is permitted)
• Total bilirubin <= 1.5 x ULN
• AST and ALT <= 2.5 x ULN, or <= 5 x ULN if patient has documented liver metastases
• Female subject must be either:

• Of non child bearing potential:

1. post-menopausal (defined as at least 1 year without any menses) prior to Screening, or

2. documented surgically sterile or status post hysterectomy (at least 1 month prior to Screening).

• Or, if of childbearing potential:

1. must have a negative urine pregnancy test at Screening, and

2. must use two forms of birth control (at least one of which must be a barrier method) starting at Screening and throughout the study period and for 30 days after final study drug administration. Acceptable forms include:

1. Established use of oral, injected or implanted hormonal methods of contraception;

2. Placement of an intrauterine device (IUD) or intrauterine system (IUS);

3. Barrier methods of contraception: Condom OR Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.

• Female subject must not be breastfeeding at Screening or during the study period and for 30 days after final study drug administration.
• Female subject must not donate ova starting at Screening and throughout the study period and for 30 days after final study drug administration.
• Male subject and their female spouse/partners who are of childbearing potential must be using highly effective contraception consisting of two forms of birth control (one of which must be a barrier method) starting at Screening and continue throughout the study period and for 30 days after final study drug administration. Acceptable forms include:

1. Established use of oral, injected or implanted hormonal methods of contraception.

2. Placement of an intrauterine device (IUD) or intrauterine system (IUS).

3. Barrier methods of contraception: Condom OR Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.

• Male subjects must not donate sperm starting at Screening and throughout the study period and for at least 30 days after final study drug administration.
• Patients must provide written informed consent to participate in the study
• Patients may not have received chemotherapy for advanced NSCLC. Previous adjuvant and/or neoadjuvant treatment for NSCLC is permitted
• Prior radiation therapy is permitted provided patients have recovered from the acute, toxic effects of radiotherapy prior to randomization. A minimum of 28 days must have elapsed between the end of radiotherapy and randomization
• Prior surgery is permitted provided that the surgery was done >= 28 days prior to randomization and adequate wound healing has occurred prior to randomization

Exclusion Criteria

• Prior exposure to agents directed at the Human Epidermal Receptor (HER) axis (eg, erlotinib, gefitinib, and cetuximab)
• Prior insulin-like growth factor -1 receptor (IGF-1R) inhibitor therapy
• Malignancies other than NSCLC within the past 3 years (exceptions if curatively treated; basal or squamous cell carcinoma of skin; locally advanced prostate cancer; ductal carcinoma in situ of breast; in situ cervical carcinoma; and superficial bladder cancer)
• Diabetes mellitus currently requiring insulinotropic or insulin therapy
• Use of proton pump inhibitors such as omeprazole within 14 days prior to randomization. H2-receptor antagonists such as ranitidine are not excluded
• Symptomatic brain metastases that are not stable, require steroids, or have required radiation and/or other related treatment (i.e., anti-epileptic medication) within 21 days prior to randomization
• Participated in any interventional clinical study or has been treated with any investigational drugs within 30 days or 5 half lives whichever is longer, prior to the initiation of Screening or during the course of the study.
• History of poorly controlled gastrointestinal disorders that could affect the absorption of study drug (eg, Crohn's disease or ulcerative colitis)
• History (within last 6 months) of significant cardiovascular disease unless the disease is well-controlled. Significant cardiac disease includes second/third degree heart block; clinically significant ischemic heart disease; superior vena cava (SVC) syndrome; poorly controlled hypertension; congestive heart failure of New York Heart Association (NYHA) Class II or worse (slight limitation of physical activity; comfortable at rest, but no ordinary physical activity results in fatigue, palpitation, or dyspnea)
• History of arrhythmia (multifocal premature ventricular contractions [PVCs], bigeminy, trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation) that is symptomatic or requires treatment (>= grade 3), left bundle branch block (LBBB), or asymptomatic sustained ventricular tachycardia are not allowed. Patients with atrial fibrillation controlled by medication are not excluded
• Mean QTcF interval >= 450 msec at screening
• Use of drugs that have a known risk of causing Torsades de Pointes (TdP) ('Torsades List' on www.azcert.org/medical-pros/drug-lists/bycategory.cfm) are prohibited within 14 days prior to randomization
• Use of strong/moderate CYP1A2 inhibitors such as ciprofloxacin and fluvoxamine. Other less potent CYP1A2 inhibitors/inducers are not excluded
• Use of strong/moderate CYP3A4 inhibitors and inducers
• History of cerebrovascular accident (CVA) within 6 months prior to randomization or that resulted in ongoing neurologic instability
• History of any psychiatric or neurologic condition that might impair the patient's ability to understand or to comply with the requirements of the study or to provide informed consent
• Pregnant or breast-feeding females
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study drug
• Active infection, serious underlying medical condition (including any type of active seizure disorder within 12 months prior to randomization), symptomatic brain metastases, or serious chronic illness that would impair the ability of the patient to receive study drug

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Astellas Pharma Inc

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Director

Role: STUDY_DIRECTOR

Astellas Pharma Global Development

Locations

University of California, San Diego/Moores Cancer Center

La Jolla, California, United States

H. Lee Moffitt Cancer Center and Research Institute

Tampa, Florida, United States

Cleveland Clinic Florida

Weston, Florida, United States

Northwestern Memorial Hospital

Chicago, Illinois, United States

Rush University Medical Center

Chicago, Illinois, United States

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Baltimore, Maryland, United States

Karmanos Cancer Institute

Detroit, Michigan, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Medical University of South Carolina

Charleston, South Carolina, United States

University of Tennessee Cancer Institute

Memphis, Tennessee, United States

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Swedish Cancer Institute

Seattle, Washington, United States

Seattle Cancer Care Alliance University of Washington

Seattle, Washington, United States

Juravinski Cancer Centre

Hamilton, Ontario, Canada

London Regional Cancer Program

London, Ontario, Canada

Princess Margaret Hospital

Toronto, Ontario, Canada

Jewish General Hospital

Montreal, Quebec, Canada

Pamela Youde Nethersole Eastern Hospital

Chai Wan, , Hong Kong

Oncocare Cancer Center

Singapore, , Singapore

Johns Hopkins Singapore International Medical Centre

Singapore, , Singapore

Chonnam National University Hwasun Hospital

Ilsimri, Hwasun-gun, South Korea

Asan Medical Center

Songpa-gu, Seoul, South Korea

Seoul National University Bundang Hospital

Seongnam-si, , South Korea

Samsung Medical Center

Seoul, , South Korea

Korea University Anam Hospital

Seoul, , South Korea

National Cancer Institute

Phayathai, Bangkok, Thailand

Maharaj Nakorn Chiangmai

Chiang Mai, , Thailand

Khon Kaen University

Khon Kaen, , Thailand

Songklanagarind Hospital, Prince of Songkla University

Songkhla, , Thailand

Countries

United States; Canada; Hong Kong; Singapore; South Korea; Thailand

Related Links

https://astellasclinicalstudyresults.com/study.aspx?ID=264

Link to results on the Astellas Clinical Study Results website

Other Identifiers

OSI-906-207

Identifier Type: -

Identifier Source: org_study_id